Author

Anish Tailor

Observed names: A. Tailor, Tailor, Anish

Institution: University College London Hospitals NHS Foundation Trust

Observed institutions: University College Hospital, University College London Hospitals NHS Foundation Trust, King's College London, University College London

ORCID: 0009-0000-6836-8555

Observed ORCID: 0009-0000-6836-8555

OpenAlex ID: A5077542770

In situ cross-linking of sodium alginate with calcium and aluminum ions to sustain the release of theophylline from polymeric matrices

2004 · Ali Nokhodchi, Anish Tailor · Il Farmaco · 103

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

2022 · Jahanzaib Khwaja, Joshua Bomsztyk, et al. · Blood Cancer Journal · 24

Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers

2023 · Gordon Cook, John Ashcroft, et al. · Frontiers in Oncology · 21

Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study

2022 · Zara Sayar, Carolyn Gates, et al. · Thrombosis Research · 16

Real‐world, single‐center experience of SARS‐CoV‐2 vaccination in immune thrombocytopenia

2022 · Philippa Woolley, Anish Tailor, et al. · Journal of Thrombosis and Haemostasis · 10

The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service

2024 · Rakesh Popat, Supratik Basu, et al. · eJHaem · 2

1859P Using deep learning with demographic and laboratory values from baseline to cycle 2 to predict subsequent renal and hepatic function

2021 · M.S. Watson, P. Chambers, et al. · Annals of Oncology · 2

Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

2026 · Wei Yee Chan, Hannah Al‐Yousuf, et al. · British Journal of Haematology

Immunoglobulin Replacement Therapy (IgRT) for the Treatment of Haematological Malignancy Associated Secondary Immunodeficiency (HM-SID) - a Large UK Tertiary Centre Experience

2024 · Zin Aung J Soe, Ahmed Eldarwi, et al. · Blood

P-048 Barriers to the Implementation of Bispecific Antibodies for Patient With Relapsed and Refractory Myeloma in the UK: Results of a National Survey

2024 · May Low, Satarupa Choudhuri, et al. · Clinical Lymphoma Myeloma & Leukemia

P918: High Responses Rates With Single Agent Belantamab Mafodotin in Relapsed Systemic Al Amyloidosis

2022 · J. Khwaja, J. Bomsztyk, et al. · HemaSphere

OC-11: Safety and efficacy of apixaban as thromboprophylaxis in multiple myeloma patients receiving chemotherapy: a prospective cohort study

2022 · Z. Sayar, C. Gates, et al. · Thrombosis Research

Works count: 43

Citation count: 178

H-index: 5

I10-index: 5